Formulation and in vitro characterization of spray-dried antisense oligonucleotide to NF-B encapsulated albumin microspheres

Journal of Microencapsulation

Volumn 26, Issue 8, 2009, Pages 692-700

  Gayakwad, Sanjay G ^a,b   Bejugam, Naveen K ^a,c   Akhavein, Nima ^a   Uddin, Nasir A ^a,d   Oettinger, Carl E ^e   D'Souza, Martin J ^a  

^a MERCER UNIVERSITY   (United States)

^b Azopharma Contract Pharmaceutical Services   (United States)

^c SRI INTERNATIONAL   (United States)

^d Barr Laboratories Inc   (United States)

^e Dialysis Clinic Inc   (United States)

Author keywords

Antisense oligonucleotide; Microspheres; NF kB, albumin; Spray drying

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICROSPHERE; PHOSPHATE BUFFERED SALINE; SERUM ALBUMIN;

ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; KINETICS; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; ZETA POTENTIAL;

ANIMALS; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; KINETICS; MICROSPHERES; NF-KAPPA B; OLIGONUCLEOTIDES, ANTISENSE; PARTICLE SIZE; SERUM ALBUMIN;

EID: 70449558745     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652040802666910     Document Type: Article

References (55)

1. Agrawal S, Temsamani J, Tang JY. 1991. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88:7595-7599.
2. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. 2002. Targeting to macrophages: Role of physicochemical properties of particulate carriers- liposomes and microspheres-on the phagocytosis by macrophages. J Contr Rel 79:29-40.
3. Akhavein N, Oettinger CW, Gayakwad SG, Addo RT, Bejugam NK, Bauer JD, et al. 2008. Treatment of adjuvant arthritis using microencapsulated antisense NF-kappaB oligonucleotides. J Microencapsulation 1-12.
4. Ardite E, Panes J, Miranda M, Salas A, Elizalde JI, Sans M, et al. 1998. Effects of steroid treatment on activation of nuclear factor kappaB in patients with inflammatory bowel disease. Br J Pharmacol 124:431-433.
5. Arifin DY, Lee LY, Wang CH. 2006. Mathematical modeling and simulation of drug release from microspheres: Implications to drug delivery systems. Adv Drug Deliv Rev 58:1274-1325.
6. Arnedo A, Espuelas S, Irache JM. 2002. Albumin nanoparticles as carriers for a phosphodiester oligonucleotide. Int J Pharm 244:59-72.
7. Auphan N, Didonato JA, Rosette C, Helmberg A, Karin M. 1995. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270:286-290.
8. Barnes PJ, Karin M. 1997. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071.
9. Bayever E, Iversen P. 1994. Oligonucleotides in the treatment of leukemia. Hematol Oncol 12:9-14.
10. Benito MJ, Murphy E, Murphy EP, Van Den Berg WB, Fitzgerald O, Bresnihan B. 2004. Increased synovial tissue NF-kappa B1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. Arthritis Rheum 50:1781-1787.
11. Berton M, Turelli P, Trono D, Stein CA, Allemann E, Gurny R. 2001. Inhibition of HIV-1 in cell culture by oligonucleotide-loaded nanoparticles. Pharm Res 18:1096-1101.
12. Billon A, Bataille B, Cassanas G, Jacob M. 2000. Development of spraydried acetaminophen microparticles using experimental designs. Int J Pharm 203:159-168.
13. Broadhead J, Rouan SK, Hau I, Rhodes CT. 1994. The effect of process and formulation variables on the properties of spray-dried beta-galactosidase. J Pharm Pharmacol 46:458-467.
14. Crooke ST, Bennett CF. 1996. Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol 36:107-129.
15. D'Souza M, Oettinger CW, Milton GV. 2000. Microspheres containing neutralizing antibodies to tumor necrosis factor-alpha and interleukin- 1 beta protect rats from Staphylococcus aureus-induced peritonitis. J Interferon Cytokine Res 20:907-913.
16. D'Souza MJ, Jin Z, Oettinger CW. 2005. Treatment of experimental septic shock with microencapsulated antisense oligomers to NF-kappaB. J Interferon Cytokine Res 25:311-320.
17. D'Souza MJ, Pourfarzib R. 1999. Improved efficacy of a microencapsulated macrophage colony stimulating factor and methotrexate in melanoma. Drug Dev Ind Pharm 25:583-590.
18. D'Acquisto F, May MJ, Ghosh S. 2002. Inhibition of nuclear factor kappa B (NF-B): An emerging theme in anti-inflammatory therapies. Mol Interv 2:22-35.
19. Dias N, Stein CA. 2002. Antisense oligonucleotides: Basic concepts and mechanisms. Mol Cancer Ther 1:347-355.
20. Feldmann M, Andreakos E, Smith C, Bondeson J, Yoshimura S, Kiriakidis S, et al. 2002. Is NF-kappaB a useful therapeutic target in rheumatoid arthritis? Ann Rheum Dis 61 Suppl 2:ii13-18.
21. Freiberg S, Zhu XX. 2004. Polymer microspheres for controlled drug release. Int J Pharm 282:1-18.
22. Geselowitz DA, Neckers LM. 1995. Bovine serum albumin is a major oligonucleotide-binding protein found on the surface of cultured cells. Antisense Res Dev 5:213-217.
23. Ghosh S, Karin M. 2002. Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl:S81-96.
24. Ghosh S, May MJ, Kopp EB. 1998. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225-260.
25. Gupta PK, Hung CT, Perrier DG. 1986. Albumin microspheres. II. Effect of stabilization temperature on the release of adriamycin. Int J Pharm 33:147-153.
26. Haswani DK, Nettey H, D'Souza MJ, Oettinger CW. 2007. In vitro evaluation and targeting of E. coli internalized by endothelial cells using albumin microspheres loaded with gentamicin. Drug Dev Ind Pharm 33:181-190.
27. Hughes MD, Hussain M, Nawaz Q, Sayyed P, Akhtar S. 2001. The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov Today 6:303-315.
28. Hunter RJ. 1981. Zeta potential in colloid science: Principles and applications. London, New York: Academic Press.
29. Jansen B, Zangemeister-Wittke U. 2002. Antisense therapy for cancer-the time of truth. Lancet Oncol 3:672-683.
30. Jones C, Burton MA, Gray BN. 1989. Albumin microspheres as vehicles for the sustained and controlled release of doxorubicin. J Pharm Pharmacol 41:813-816.
31. Karin M, Ben-Neriah Y. 2000. Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev Immunol 18:621-663.
32. Khaled AR, Soares LS, Butfiloski EJ, Stekman I, Sobel ES, Schiffenbauer J. 1997. Inhibition of the p50 (NKkappaB1) subunit of NF-kappaB by phosphorothioate-modified antisense oligodeoxynucleotides reduces NF-kappaB expression and immunoglobulin synthesis in murine B cells. Clin Immunol Immunopathol 83:254-263.
33. Kluth DC, Rees AJ. 1999. New approaches to modify glomerular inflammation. J Nephrol 12:66-75.
34. Lanke SS, Gayakwad SG, Strom JG, D MJ. 2008. Oral delivery of low molecular weight heparin microspheres prepared using biodegradable polymer matrix system. J Microencapsulation 1-8.
35. Lebedeva I, Benimetskaya L, Stein CA, Vilenchik M. 2000. Cellular delivery of antisense oligonucleotides. Eur J Pharm Biopharm 50:101-119.
36. Lee SW, Kim MH, Kim CK. 1999. Encapsulation of ethanol by spray drying technique: Effects of sodium lauryl sulfate. Int J Pharm 187:193-218
37. Lin W, Garnett MC, Davis SS, Schacht E, Ferruti P, Illum L. 2001. Preparation and characterisation of rose Bengal-loaded surface-modified albumin nanoparticles. J Contr Rel 71:117-126.
38. Mathew ST, Devi SG, Kv S. 2007. Formulation and evaluation of ketorolac tromethamine-loaded albumin microspheres for potential intramuscular administration. AAPS PharmSciTech 8:14.
39. Nettey H, Haswani D, D'Souza M, Oettinger C. 2007. In vitro antimicrobial effect of encapsulated vancomycin on internalized Staphylococcus aureus within endothelial cells. Drug Dev Ind Pharm 33:133-139.
40. Oettinger CW, D'Souza MJ, Akhavein N, Peer GT, Taylor FB, Kinasewitz GT. 2007. Pro-inflammatory cytokine inhibition in the primate using microencapsulated antisense oligomers to NF-kappaB. J Microencapsulation 24:337-348.
41. Pahl HL. 1999. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853-6866.
42. Palmieri GF, Bonacucina G, Di Martino P, Martelli S. 2001. Spray-drying as a method for microparticulate controlled release systems preparation: Advantages and limits. I. Water-soluble drugs. Drug Dev Ind Pharm 27:195-204.
43. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. 1995. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270:283-286.
44. Schlaak JF, Barreiros AP, Pettersson S, Schirmacher P, Meyer Zum Buscenfelde KH, Neurath MF. 2001. Antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappaB abrogate fulminant septicshock induced by S. typhimurium in mice. Scand J Immunol 54:396-403.
45. Schottelius AJ, Dinter H. 2006. Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat Res 130:67-87.
46. Schwendeman SP. 2002. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit Rev Ther Drug Carrier Syst 19:73-98.
47. Shah AU, D'Souza MJ. 1999. Sustained-release interleukin-12 microspheres in the treatment of cancer. Drug Dev Ind Pharm 25:995-1004.
48. Siwale RC, Oettinger CW, Balakrishna Pai S, Addo R, Uddin N, Siddig A, et al. 2008. Formulation and characterization of catalase in albumin microspheres. J Microencapsulation 1-9.
49. Srinivasan SK, Tewary HK, Iversen PL. 1995. Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Antisense Res Dev 5:131-139.
50. Tari AM. 2000. Preparation and application of liposome-incorporated oligodeoxynucleotides. Methods Enzymol 313:372-388.
51. Tsoulfas G, Geller DA. 2001. NF-kappaB in transplantation: Friend or foe? Transpl Infect Dis 3:212-219.
52. Vehring R. 2008. Pharmaceutical particle engineering via spray drying. Pharm Res 25:999-1022.
53. Wartlick H, Spankuch-Schmitt B, Strebhardt K, Kreuter J, Langer K. 2004. Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles. J Contr Rel 96:483-495.
54. Yeo Y, Park K. 2004. Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharm Res 27:1-12.
55. Zhaowei J, D'Souza MJ, Oettinger CW. 2007. Reversal of LPS induced endothelial cell TNF synthesis and increased permeability with microencapsulated antisense oligomers to NF-kappaB. J Microencapsulation 24:596-607.